Taldefgrobep alfa clinical trials
Also written RO7239361 and BHV-2000.
How each study uses taldefgrobep alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Hoffmann-La Roche (4) · Biohaven Pharmaceuticals, Inc. (1) · Biohaven Therapeutics Ltd. (1)
Studies
Open first, then newest update. How each study uses taldefgrobep alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular AtrophyActive, not recruitingPhase 3Biohaven Pharmaceuticals, Inc.NCT05337553Written as taldefgrobep alfa
- Taldefgrobep Alfa in Adults With Overweight and ObesityActive, not recruitingPhase 2Biohaven Therapeutics Ltd.NCT07281495Written as Taldefgrobep Alfa
- Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyCompletedPhase 2/3Hoffmann-La RocheNCT03039686Written as RO7239361
- Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMDTerminatedPhase 1/2Hoffmann-La RocheNCT02515669Written as RO7239361
- Compare Bioavailability of RO7239361 After Subcutaneous InjectionCompletedPhase 1Hoffmann-La RocheNCT03100630Written as RO7239361
- Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult SubjectsCompletedPhase 1Hoffmann-La RocheNCT02145234Written as BMS-986089
Codes
What other systems call taldefgrobep alfa · ClinicalTrials.gg INT015410
- UNII (FDA) 766C38JSARTALDEFGROBEP ALFAOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 766C38JSAR | TALDEFGROBEP ALFA | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.